아이엠비디엑스

핵심기술

보이지 않는 암을 빠르고 정확하게 발견할 수 있습니다.

논문

게시물 목록
번호	년도	제목	저널명	링크
30	2025	Whole genome DNA methylation patterns in tissue and cfDNA associated with fibrosis reflect the complex signature of MASLD Abstract Whole-genome DNA methylation sequencing (WGMS) of liver tissue and circulating cell-free DNA (cfDNA) in patients with MASLD identified fibrosis-associated methylation patterns in both sample types, along with clear sex-specific and immune-related signals. These results demonstrate the potential of cfDNA-based WGMS as a non-invasive approach for comprehensively monitoring MASLD-related fibrosis. Purpose The study aimed to investigate the relationship between whole-genome DNA methylation (DNAm) patterns and fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by analyzing both liver tissue and circulating cell-free DNA (cfDNA). Prior research on MASLD methylation was limited to specific CpG sites or tissue only, with little consideration of sex differences. This research sought to address these gaps and explore whether cfDNA methylation profiles could reflect fibrosis-associated changes non-invasively. Materials and Methods Liver tissue and cfDNA samples were collected fr\|om patients with MASLD. Whole-genome methylation sequencing (WGMS) was performed on both sample types. After quality filtering, the data were grouped by sex and sample type. CpG bins showing significant correlation with fibrosis stage using statistical filtering were selected. Pathway analyses were conducted based on genomic locations of significant CpG bins. Additionally, cell type deconvolution was performed to infer cellular contributions to the methylation signal, and comparative analyses between tissue and cfDNA profiles were carried out. Results The WGMS analysis identified overlapping and distinct methylation patterns associated with fibrosis across tissue and cfDNA, and between males and females. Pathway analysis revealed multiple fibrosis-related signaling pathways, including Wnt and Notch signaling, with sex-specific differences. Tissue samples showed immune cell signatures associated with fibrosis. cfDNA analysis reflected increased liver-derived DNA fragments and methylation changes similar to tissue patterns, indicating that cfDNA captures fibrosis-associated alterations. Predictive modeling using cfDNA methylation also showed potential for distinguishing fibrosis severity. Conclusions Whole-genome methylation sequencing reveals complex DNA methylation changes associated with MASLD and fibrosis in both tissue and cfDNA. The findings demonstrate that cfDNA WGMS can capture fibrosis-related epigenetic alterations and holds promise as a non-invasive diagnostic approach for fibrosis in MASLD, potentially enabling blood-based detection and monitoring of disease progression. Whole genome DNA methylation patterns in tissue and cfDNA associated with fibrosis reflect the complex signature of MASLD 링크보기	PLOS One	링크보기
29	2025	Enhanced Detection of Druggable Mutations in Non–Small Cell Lung Cancer Using Targeted Collection of Bronchial Washing Fluid Compared With Plasma and Tumor Tissue Abstract PurposeNext-generation sequencing (NGS) has become the gold standard for the molecular testing of patients with non–small cell lung cancer (NSCLC). This prospective study evaluated the performance of NGS using cell-free tumor DNA (ctDNA) extracted fr\|om bronchial washing fluid (BWF) collected via a targeted washing technique to detect druggable mutations. Materials and Methods All study participants simultaneously underwent NGS using three sample types: (1) BWF, (2) plasma, and (3) tumor tissue collected during bronchoscopy. The full patient set (FPS) included all enrolled patients, whereas the analysis intent group (AIG) included patients who underwent successful NGS across all specimen types (BWF, plasma, and tissue). Results Sixty and 50 patients were included in the FPS and AIG groups, respectively. In FPS, the detection rate of druggable mutations in BWF using NGS was 65%, which was significantly higher than that of plasma (47%) and tissue samples (48%; P 5 .003 and P 5 .002, respectively). In the AIG, the concordance rate for detecting druggable mutations between BWF and tissue samples was 94%. In addition, the detection rate of co-occurring genetic alterations in BWF using NGS was significantly higher than that in plasma samples (92% v 64%, P 5 .001), whereas it was comparable with that in tissue samples (92% v 94%, P 5 1.000). No significant adverse events occurred during the BWF collection. ConclusionsNGS using ctDNA fr\|om BWF obtained through a targeted washing technique is a feasible and reliable method for genomic profiling of NSCLC, providing a promising approach for identifying druggable mutations. Enhanced Detection of Druggable Mutations in Non–Small Cell Lung Cancer Using Targeted Collection of Bronchial Washing Fluid Compared With Plasma and Tumor Tissue 링크보기	JCO Precision Oncology	링크보기
28	2025	Pairwise analysis of plasma cell-free DNA before and after palliative second-line paclitaxel plus ramucirumab treatment in patients with metastatic gastric cancer Abstract Background This study compared plasma cell-free DNA (cfDNA) and tumor tissue DNA (ttDNA) to explore the clinical applicability of cfDNA in patients with metastatic gastric cancer (mGC) receiving palliative second-line paclitaxel + ramucirumab treatment. Methods Targeted sequencing of 106 genes was conducted using germline DNA and cfDNA at baseline (baseline-cfDNA) and progressive disease (PD-cfDNA). The results were compared with those of ttDNA-based cancer panel data. Results Of 76 consecutive patients, 46 (27 males; median age 57.5 [range, 32–73] years) who had all three samples were included. Combined analysis of ttDNA and baseline-cfDNA revealed that TP53 (58.7%) was the most frequently mutated gene, followed by CDH1 (26.1%), KRAS (21.7%), and APC (13.0%). For these genes, the sensitivity and positive predictive value of baseline-cfDNA over ttDNA were 71.8% and 51.9%, respectively. When baseline-cfDNA and PD-cfDNA results were combined, 34 patients (73.9%) were found to have additional mutations compared with ttDNA results alone. PD-cfDNA analysis revealed 14 novel pathogenic mutations in ten patients (21.7%). At baseline, patients with a high circulating tumor DNA fraction concentration showed a significantly shorter progression-free survival (PFS) (P = 0.016) in univariable and multivariable analyses. High maximal variant allele frequency (VAF) (P = 0.022), high sum of VAF (P = 0.028), and high TP53 VAF (P = 0.022) were associated with worse PFS in univariable analysis. Conclusions Although cfDNA alone cannot replace ttDNA entirely, cfDNA analysis revealed additional mutations. Notably, PD-cfDNA analysis revealed novel pathogenic mutations that emerged during treatment. Moreover, the baseline circulating tumor DNA fraction concentration and VAF values were associated with longer PFS. Pairwise analysis of plasma cell-free DNA before and after palliative second-line paclitaxel plus ramucirumab treatment in patients with metastatic gastric cancer 링크보기	Gastric Cancer	링크보기
27	2025	Blood Circulating Tumor DNA‐based Genomic Profiling and Serial Analysis in Patients With Advanced Biliary Tract Cancer Abstract Background/Aim: This study aimed to identify mutation profile similarities between tissue and circulating tumor DNA (ctDNA) and to explore driver mutations as potential prognostic or predictive biomarkers or druggable targets in patients with advanced biliary tract cancer (BTC). Patients and Methods: We prospectively enrolled 18 patients with advanced BTC and analyzed next-generation sequencing data fr\|om 60 ctDNA samples using AlphaLiquid® 100. This assay screens up to 118 genes for single-nucleotide variants (SNVs) and insertion or deletions (INDELs), 27 genes for copy number alterations (CNAs), and 10 genes for fusions. We examined the intra-patient tissue-ctDNA concordance and studied the association between ctDNA variant allele frequency (VAF) and survival. Results: A total of seven gallbladder cancer cases, six intrahepatic cholangiocarcinoma cases, and five extrahepatic cholangiocarcinoma cases were observed. Among these cases, tumor tissues were available for 16 patients. Genetic alterations were detected in 88% (14/16) of tissue DNA samples and 89% (16/18) of samples with ctDNA at baseline. The most common genes altered in ctDNA were TP53 (n=11), ERBB3 (n=3), and KRAS (n=3). There was a 29% overlap in somatic SNVs/INDELs and a 60% overlap in CNAs between tissue DNA and ctDNA, while no fusion variant was detected. The sensitivity and positive predictive value of ctDNA for all types of somatic mutations were 47% and 43%, respectively. Among the 14 patients whose serial ctDNA was analyzed, 10 showed changes in ctDNA. A high pre-treatment VAF (>4.0%) was associated with poor overall survival. Conclusion: ctDNA sequencing can successfully identify molecular genetic alterations in patients with advanced BTC, providing insights into potential biomarkers and therapeutic targets. Blood Circulating Tumor DNA‐based Genomic Profiling and Serial Analysis in Patients With Advanced Biliary Tract Cancer 링크보기	Anticancer Research	링크보기
26	2025	An open-label, phase IB/II study of abemaciclib with paclitaxel for tumors with CDK4/6 pathway genomic alterations Abstract Background Disruption of cyclin D-dependent kinases (CDKs), particularly CDK4/6, drives cancer cell proliferation via abnormal protein phosphorylation. This open-label, single-arm, phase Ib/II trial evaluated the efficacy of the CDK4/6 inhibitor, abemaciclib, combined with paclitaxel against CDK4/6-activated tumors. Patients and methods Patients with locally advanced or metastatic solid tumors with CDK4/6 pathway aberrations were included. Based on phase Ib, the recommended phase II doses were determined as abemaciclib 100 mg twice daily and paclitaxel 70 mg/m2 on days 1, 8, and 15, over 4-week-long cycles. The primary endpoint for phase II was the overall response rate (ORR). The secondary endpoints included the clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and safety. Tissue-based next-generation sequencing and exploratory circulating tumor DNA analyses were carried out. Results Between February 2021 and April 2022, 30 patients received abemaciclib/paclitaxel (median follow-up: 15.7 months), and 27 were included in the efficacy analysis. CDK4/6 amplification (50%) and CCND1/3 amplification (20%) were common activating mutations. The ORR was 7.4%, with two partial responses, and the CBR was 66.7% (18/27 patients). The median OS and PFS were 9.9 months [95% confidence interval (CI) 5.7-14.0 months] and 3.5 months (95% CI 2.6-4.3 months), respectively. Grade 3 adverse events (50%, 21 events) were mainly hematologic. Genetic analysis revealed a ‘poor genetic status’ subgroup characterized by mutations in key signaling pathways (RAS, Wnt, PI3K, and NOTCH) and/or CCNE amplification, correlating with poorer PFS. Conclusion Abemaciclib and paclitaxel showed moderate clinical benefits for CDK4/6-activated tumors. We identified a poor genetic group characterized by bypass signaling pathway activation and/or CCNE amplification, which negatively affected treatment response and survival. Future studies with homogeneous patient groups are required to validate these findings. An open-label, phase IB/II study of abemaciclib with paclitaxel for tumors with CDK4/6 pathway genomic alterations 링크보기	ESMO Open	링크보기